Safusidenib not checked
Nuvation Bio · DS-1001b · AB-218
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.”In the company’s words, NCT05303519 on ClinicalTrials.gov
- Tested for
- Oligodendroglioma (3 trials), Glioma (2 trials), IDH1-mutant Glioma (2 trials), Astrocytoma IDH Mutant Grade 2 (2 trials), Astrocytoma, Grade IV, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, IDH-Mutant, Grade 2 and 9 more
- Main trialPhase 3
- “This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to evaluate the efficacy of maintenance safusidenib treatment versus placebo in IDH1-mutant Grade 2 or Grade 3 astrocytoma with high-risk features or IDH1-mutant Grade 4 astrocytoma, following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Part 2 will be randomized,…”In the company’s words, NCT05303519 on ClinicalTrials.gov
- Other names
- DS-1001b · Investigational · AB-218
Other drugs for Oligodendroglioma
- OlutasidenibRigel Pharmaceuticals · Forma Therapeutics, Inc. · Phase 2
- ONC206Jazz Pharmaceuticals · Phase 1
- IDH305Novartis · Phase 1
- OKN-007Oblato, Inc. · Phase 1
- DabrafenibNovartis · Marketed (Phase 4 trial)
- TrametinibNovartis · Marketed (Phase 4 trial)
Coming up3
- 1 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- May 2029Phase 3 trial completes · ClinicalTrials.gov
- Sep 2030Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 1 Dec 2028 | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | |
| Phase 3Not yet recruiting | May 2029 | Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma | |
| Phase 2Active, not recruiting | 10 Mar 2023 | A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma | |
| Phase 2Recruiting | Sep 2030 | Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease | |
| Phase 1Completed | 31 Jan 2021 | Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas | |
| Phase 1Terminated | 15 Aug 2024 | IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026